PT  - JOURNAL ARTICLE
AU  - Rebecca Yee
AU  - Thao Truong
AU  - Pia S. Pannaraj
AU  - Natalie Eubanks
AU  - Emily Gai
AU  - Jaycee Jumarang
AU  - Lauren Turner
AU  - Ariana Peralta
AU  - Yesun Lee
AU  - Jennifer Dien Bard
TI  - Saliva is a promising alternative specimen for the detection of SARS-CoV-2 in children and adults
AID  - 10.1101/2020.10.25.20219055
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.25.20219055
4099  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219055.short
4100  - http://medrxiv.org/content/early/2020/10/27/2020.10.25.20219055.full
AB  - Testing efforts for SARS-CoV-2 have been burdened by the scarcity of testing materials and personal protective equipment for healthcare workers. The simple and painless process of saliva collection allows for widespread testing, but enthusiasm is hampered by variable performance compared to nasopharyngeal swab (NPS) samples. We prospectively collected paired NPS and saliva samples from a total of 300 unique adult and pediatric patients. SARS-CoV-2 RNA was detected in 32.2% (97/300) of the individuals using the TaqPath COVID-19 Combo Kit (Thermo Fisher). Performance of saliva and NPS were compared against the total number of positives regardless of specimen type. The overall concordance for saliva and NPS was 91.0% (273/300) and 94.7% (284/300), respectively. The positive percent agreement (PPA) for saliva and NPS was 81.4% (79/97) and 89.7% (87/97), respectively. Saliva detected 10 positive cases that were negative by NPS. In symptomatic and asymptomatic pediatric patients not previously diagnosed with COVID-19, the performances of saliva and NPS were comparable (PPA: 82.4% vs 85.3%). The overall PPA for adults were 83.3% and 90.7% for saliva and NPS, respectively, with saliva detecting 4 cases less than NPS. However, saliva performance in symptomatic adults was identical to NPS (PPA of 93.8%). With lower cost and self-collection capabilities, saliva can be an appropriate alternative sample choice to NPS for detection of SARS-CoV-2 in children and adults.Summary Saliva is an acceptable alternative specimen compared to nasopharyngeal swabs for detection of SARS-CoV-2. Specifically, saliva demonstrated comparable performance to nasopharyngeal swabs in symptomatic and asymptomatic pediatric patients and in symptomatic adults.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded in part by the National Institutes of Health [U01 AI144616-02S1 to P.S.P.].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study design conducted at Childrens Hospital Los Angeles was approved by the Institutional Review Board under IRB #CHLA-20-00124 and CHLA-18-00098.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe manuscript contains all relevant data.